Analysts Set $4.35 Target Price for Fulgent Genetics (FLGT)

Shares of Fulgent Genetics (NASDAQ:FLGT) have earned a consensus broker rating score of 3.00 (Hold) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a hold recommendation. Fulgent Genetics’ rating score has declined by 50% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.

Brokers have set a twelve-month consensus target price of $4.35 for the company and are predicting that the company will post ($0.05) earnings per share for the current quarter, according to Zacks. Zacks has also given Fulgent Genetics an industry rank of 209 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

Several equities analysts have recently issued reports on FLGT shares. Piper Jaffray downgraded shares of Fulgent Genetics from an “overweight” rating to a “neutral” rating in a report on Thursday, March 1st. Credit Suisse Group reduced their price target on shares of Fulgent Genetics from $6.50 to $6.00 and set an “outperform” rating for the company in a report on Thursday, March 1st. Finally, Zacks Investment Research raised shares of Fulgent Genetics from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 9th.



Fulgent Genetics stock traded down $0.24 during mid-day trading on Monday, reaching $3.76. The company’s stock had a trading volume of 47,917 shares, compared to its average volume of 18,441. Fulgent Genetics has a twelve month low of $2.72 and a twelve month high of $11.10. The company has a market cap of $71.47, a PE ratio of -34.18 and a beta of 0.31.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Mutual Advisors LLC acquired a new position in shares of Fulgent Genetics during the fourth quarter valued at $1,662,000. Royce & Associates LP acquired a new position in shares of Fulgent Genetics during the fourth quarter valued at $219,000. Thompson Davis & CO. Inc. acquired a new position in shares of Fulgent Genetics during the fourth quarter valued at $154,000. Finally, Granahan Investment Management Inc. MA boosted its holdings in shares of Fulgent Genetics by 145.5% during the third quarter. Granahan Investment Management Inc. MA now owns 238,232 shares of the company’s stock valued at $1,141,000 after acquiring an additional 141,182 shares during the period. 7.93% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://stocknewstimes.com/2018/04/17/analysts-set-4-35-target-price-for-fulgent-genetics-flgt.html.

About Fulgent Genetics

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Get a free copy of the Zacks research report on Fulgent Genetics (FLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply